Mikolaskova Iveta, Crnogorac-Jurcevic Tatjana, Smolkova Bozena, Hunakova Luba
Institute of Immunology, Faculty of Medicine, Comenius University, Odborarske Namestie 14, 811 08 Bratislava, Slovakia.
Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK.
Biology (Basel). 2023 Jan 19;12(2):158. doi: 10.3390/biology12020158.
The correlation between pancreatic ductal adenocarcinoma (PDAC) and diabetes-related mechanisms support the hypothesis that early therapeutic strategies targeting diabetes can contribute to PDAC risk reduction and treatment improvement. A systematic review was conducted, using PubMed, Embase and Cochrane Library databases, to evaluate the current evidence from clinical studies qualitatively examining the efficacy of four natural products: Curcumin- L.; Thymoquinone- L.; Genistein- L.; L.; and a low-carbohydrate ketogenic diet in type 2 diabetes (T2D) and PDAC treatment. A total of 28 clinical studies were included, showing strong evidence of inter-study heterogeneity. Used as a monotherapy or in combination with chemo-radiotherapy, the studied substances did not significantly improve the treatment response of PDAC patients. However, pronounced therapeutic efficacy was confirmed in T2D. The natural products and low-carbohydrate ketogenic diet, combined with the standard drugs, have the potential to improve T2D treatment and thus potentially reduce the risk of cancer development and improve multiple biological parameters in PDAC patients.
胰腺导管腺癌（PDAC）与糖尿病相关机制之间的关联支持了这样一种假说，即针对糖尿病的早期治疗策略有助于降低PDAC风险并改善治疗效果。本研究进行了一项系统评价，利用PubMed、Embase和Cochrane图书馆数据库，定性评估来自临床研究的现有证据，这些研究考察了四种天然产物：姜黄素-L.；百里醌-L.；染料木黄酮-L.；L.；以及低碳水化合物生酮饮食在2型糖尿病（T2D）和PDAC治疗中的疗效。共纳入28项临床研究，结果显示研究间存在显著异质性。这些被研究的物质作为单一疗法或与放化疗联合使用时，并未显著改善PDAC患者的治疗反应。然而，在T2D中证实了其显著的治疗效果。这些天然产物和低碳水化合物生酮饮食与标准药物联合使用，有可能改善T2D的治疗，从而潜在地降低癌症发生风险，并改善PDAC患者的多种生物学参数。
